RE:RE:RE:RE:RE:CZO IS NOT DE-RISKED"Not long ago Gagnon was so sure about the PGX tech that he decided to build a plan in Europe , now i guess he is not so sure anymore he wants to scale it up at university to make sure it is close enough to the rescue party."
The biotech market has been in its worst bear merket in history. 25% of the industry has been trading below the value of cash on the balance sheet in recent months. Inflation has destroyed biotech. There is limited funding for capital investment in the development stage given the markets. Europe also entered its largest war in 70 years given Putin's invasion of Ukraine. Germany has been in an energy crisis as a result. We are fortunate CZO didn't commit to a large plant there. CZO is taking a step-wise approach and will build a plant 5-10 larger than the pilot plant to further de-risk and to demonstrate to partners. It can do this with available resources. Given falling prices due to the anticipated recession and central bank tightening CZO could secure much better pricing for its larger plant in the future.
"Also what happened wit the collaboration between czo and the angiogenesis fondation????"
Sometimes you don't tell the world what you know right way years before you are on the market. Potential competitors could get excited. This is a business. We don't know the results from the Angiogenesis Foundation good or bad. The study could have simply been extended as studies often are. We do know that CZO had certain promising dose-dependent results that led to the study and that avenanthramide is now approved by Health Canada for human trials.
"This research collaboration has been established based on preliminary in vitro results showing that Ceapro’s pharmaceutical grade formulations of beta-glucan and avenanthramides stimulate the proliferation and migration of vascular endothelial cells in a dose-dependent manner." News release
“Endothelial cell stimulation is a hallmark of, and a requirement for, wound healing,” commented Dr. Vincent W. Li, Chief Scientific Officer of the Angiogenesis Foundation. “Given that Ceapro products have demonstrated in vitro activity that may impact healing at the cellular level, we expect to further characterize this biological activity using well-established in vivo models and assess their potential applications to a variety of functional health benefits. These benefits include tissue regeneration and repair as well as disease conditions such as COVID-19 and post-COVID-19, which are associated with severe blood vessel damage leading to thrombosis in the lungs and other organs. We believe this has the potential to address a root cause of such complications.” News release